Compile Data Set for Download or QSAR
maximum 50k data
Found 44 Enz. Inhib. hit(s) with all data for entry = 1780
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339899((3S)-1-[(trans-4-{(1S)-1-[(tert-Butoxycarbonyl)ami...)
Affinity DataIC50:  6nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339903(US9758480, 114)
Affinity DataIC50:  7nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339926(Pentyl 5-{[(3S)-1-[(trans-4-{(1S)-1-[(tert-butoxyc...)
Affinity DataIC50:  8nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339882(5-{(2S,3S)-1-[trans-4-(tert-Butoxycarbonylaminomet...)
Affinity DataIC50:  9nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339927(Cyclopropylmethyl 5-{[(3S)-1-[(trans-4-{(1S)-1-[(t...)
Affinity DataIC50:  10nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339889(US9758480, 35)
Affinity DataIC50:  14nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339888(US9758480, 34)
Affinity DataIC50:  28nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339925(Tetrahydro-2H-pyran-4-ylmethyl 5-{[(3S)-1-[(trans-...)
Affinity DataIC50:  29nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339890(US9758480, 38)
Affinity DataIC50:  30nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339920(US9758480, 184 | tert-Butyl [(1S)-1-(trans-4-{[(2S...)
Affinity DataIC50:  30nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339919(Cyclopentylmethyl 5-{[(3S)-1-[(trans-4-{(1S)-1-[(t...)
Affinity DataIC50:  33nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339896(5-[(2S,3S)-1-{trans-4-[(1S)-1-(tert-Butoxycarbonyl...)
Affinity DataIC50:  34nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339884(5-{(2S,3S)-1-[trans-4-(tert-Butoxycarbonylaminomet...)
Affinity DataIC50:  34nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339906((2S)-Tetrahydrofuran-2-ylmethyl 5-({(3S)-1-[(trans...)
Affinity DataIC50:  43nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339893(5-[(2S,3S)-1-{trans-4-[1-(tert-Butoxycarbonyl)amin...)
Affinity DataIC50:  45nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339910(US9758480, 134)
Affinity DataIC50:  54nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339921(US9758480, 186 | tert-Butyl [(1S)-1-(trans-4-{[(2S...)
Affinity DataIC50:  60nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339891(5-[(2S,3S)-1-{trans-4-[1-(tert-Butoxycarbonyl)amin...)
Affinity DataIC50:  63nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339905(US9758480, 118)
Affinity DataIC50:  65nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339912(US9758480, 138)
Affinity DataIC50:  72nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339917(US9758480, 170)
Affinity DataIC50:  76nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339887(5-[(2S,3S)-1-{trans-4-[1-(tert-Butoxycarbonyl)amin...)
Affinity DataIC50:  82nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339895(US9758480, 50)
Affinity DataIC50:  84nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339894(5-[(2S,3R)-1-{trans-4-[1-(tert-Butoxycarbonylamino...)
Affinity DataIC50:  90nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339900(US9758480, 102)
Affinity DataIC50:  93nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339898(US9758480, 96)
Affinity DataIC50:  98nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339909(US9758480, 133)
Affinity DataIC50:  99nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339874(5-{cis-1-[trans-4-(Aminomethyl)cyclohexanecarbonyl...)
Affinity DataIC50:  125nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339876(US9758480, 14 | tert-Butyl trans-4-{cis-2-[3-fluor...)
Affinity DataIC50:  130nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339916(US9758480, 148)
Affinity DataIC50:  140nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339902(US9758480, 113)
Affinity DataIC50:  145nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339908(4-Methoxybutyl 5-({(3S)-1-[(trans-4-{(1S)-1-[(tert...)
Affinity DataIC50:  195nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339915(US9758480, 147)
Affinity DataIC50:  205nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339897(US9758480, 55)
Affinity DataIC50:  220nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339922((3S)-1-[(trans-4-{(1S)-1-[(tert-Butoxycarbonyl)ami...)
Affinity DataIC50:  285nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339918((2S)-2-Methoxypropyl 5-{[(3R)-1-[(trans-4-{(1S)-1-...)
Affinity DataIC50:  300nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339911(US9758480, 137)
Affinity DataIC50:  380nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339907(US9758480, 122)
Affinity DataIC50:  690nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339914(US9758480, 146)
Affinity DataIC50:  916nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339904(US9758480, 115)
Affinity DataIC50:  1.50E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339901(US9758480, 103)
Affinity DataIC50:  2.35E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339913(3-Ethoxypropyl 5-({(3R)-1-[(trans-4-{(1S)-1-[(tert...)
Affinity DataIC50:  3.45E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339923(US9758480, 196)
Affinity DataIC50:  3.50E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339924(3-(Morpholin-4-yl)propyl 5-{[(3S)-1-[(trans-4-{(1S...)
Affinity DataIC50:  4.10E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent